Cargando…
Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide
The goals of COPD therapy are to prevent and control symptoms, reduce the frequency and severity of exacerbations, and improve exercise tolerance. The triple combination therapy of inhaled corticosteroids (ICSs), long-acting beta(2) agonists (LABAs), and long-acting muscarinic antagonists (LAMAs) ha...
Autores principales: | Singh, Dave, Corradi, Massimo, Spinola, Monica, Papi, Alberto, Usmani, Omar S, Scuri, Mario, Petruzzelli, Stefano, Vestbo, Jørgen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638574/ https://www.ncbi.nlm.nih.gov/pubmed/29062229 http://dx.doi.org/10.2147/COPD.S146822 |
Ejemplares similares
-
Lung Deposition of Inhaled Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide in Healthy Volunteers and Asthma: The STORM Study
por: Usmani, Omar S., et al.
Publicado: (2022) -
Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma
por: Kuna, Piotr, et al.
Publicado: (2022) -
The efficacy of extrafine beclomethasone dipropionate–formoterol fumarate in COPD patients who are not “frequent exacerbators”: a post hoc analysis of the FORWARD study
por: Singh, Dave, et al.
Publicado: (2017) -
Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
por: Mantero, Marco, et al.
Publicado: (2018) -
Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease
por: Singh, Dave, et al.
Publicado: (2016)